Gretchen Baldwin, PA
Medical · Jacksonville, FLNPI 1679817266
Payments from drug & device makers
Across 125 payments — averaging $21.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$459
- AbbVie$379
- Bayer$236
- Lilly USA, LLC$216
- GSK$121
- Sumitomo Pharma America, Inc.$121
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,654100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $459 |
| AbbVie | 17 | $379 |
| Bayer | 11 | $236 |
| Lilly USA, LLC | 12 | $216 |
| GSK | 7 | $121 |
| Sumitomo Pharma America, Inc. | 6 | $121 |
| Pfizer | 6 | $112 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $106 |
| Vertos Medical, Inc. | 1 | $105 |
| Novo Nordisk | 7 | $103 |
| Esperion Therapeutics, Inc. | 4 | $80 |
| Medtronic | 2 | $66 |
| Amgen | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Philips North America LLC | 2 | $48 |
| Dexcom, Inc. | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Nestle Healthcare Nutrition Inc. | 1 | $26 |
| Abbott | 1 | $23 |
| Johnson & Johnson | 2 | $23 |
| Abiomed | 1 | $23 |
| Novartis | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Insulet Corporation | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Cranial Technologies, Inc | 1 | $16 |
| Inogen, Inc. | 1 | $15 |
| Vistapharm, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$122
- AIRSUPRA$122
- BREZTRI$122
- mild Device Kit$105
How this compares
$2,661 in reported general payments places this provider in the 75th percentile of 2,031 medical providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $129,613 |
| JardianceEmpagliflozin | 84 | $122,157 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $81,767 |
| LinzessLinaclotide | 59 | $69,241 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 84 | $66,825 |
| EliquisApixaban | 55 | $57,789 |
| GemtesaVibegron | 51 | $55,906 |
| FarxigaDapagliflozin Propanediol | 31 | $41,395 |
| MounjaroTirzepatide | 36 | $38,736 |
| XifaxanRifaximin | 11 | $35,361 |
| TrulicityDulaglutide | 27 | $31,910 |
| RybelsusSemaglutide | 26 | $31,613 |
| EntrestoSacubitril/Valsartan | 15 | $26,070 |
| JanuviaSitagliptin Phosphate | 16 | $24,721 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $16,409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $103 | $161,227158 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $20 | $131,905104 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $459 | $120,644157 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $121 | $88,536127 claims |
| Lilly USA, LLCMounjaro, Trulicity | $216 | $70,64663 claims |
| AbbVieLinzess | $379 | $69,24159 claims |
| PfizerEliquis | $112 | $57,78955 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $121 | $55,90651 claims |
| NovartisEntresto | $21 | $26,07015 claims |
| Johnson & JohnsonXarelto | $23 | $11,87511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,031 medical providers in Florida.
Other medical in Jacksonville
- Eric PonderJacksonville$67K
- Kristen DixonJacksonville$54K
- Amanda MichaudJacksonville$45K
- Paul DuffJacksonville$35K
- Ina SansonJacksonville$15K
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.